Manning & Napier Advisors LLC Lowers Holdings in Zoetis Inc. $ZTS

Manning & Napier Advisors LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 385,723 shares of the company’s stock after selling 17,084 shares during the quarter. Manning & Napier Advisors LLC owned approximately 0.09% of Zoetis worth $56,439,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC boosted its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. REAP Financial Group LLC increased its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC raised its holdings in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the period. ORG Partners LLC raised its stake in shares of Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after buying an additional 84 shares during the period. Finally, Financial Consulate Inc. purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $39,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $124.60 on Wednesday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a market cap of $54.91 billion, a P/E ratio of 20.98, a PEG ratio of 2.55 and a beta of 0.97. The company has a 50-day moving average price of $122.90 and a 200 day moving average price of $140.04. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the company earned $1.58 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is 33.67%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ZTS shares. KeyCorp assumed coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zoetis in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.